needed effects
active ingredient
orgaran
unwanted side effects
medical attention
taking
emergency help
following effects
danaparoid side effects
medical attention
body
medicine
side effects
health care professional
side effects
following side effects
fatal bleeding episode
patient with renal insufficiency
possible danaparoid-associated mortality
bleeding
thrombosis
septic shock
patients
danaparoid
cross-reactivity with heparin-induced antibody than some low molecular weight heparins
fresh patient plasma
active ingredient
orgaran
tests
positive cross-reactivity with heparin-induced antibody
patients
unfractionated heparin
low-molecular-weight heparin
developing
developing heparin-induced thrombocytopenia
hit
hit-related thromboembolic complications
transient ischemic attack
stroke
heparin-induced thrombocytopenia
hit
prothrombotic reaction
patients
unfractionated heparin
patients
low molecular weight heparin
lmwh
decrease in platelet count
hit
days
starting heparin
patients with a previous exposure
heparin
abrupt decrease in platelets
restarting heparin
patients with lmwh-induced hit
longer delay in the onset of symptoms
unfractionated heparin
following discontinuation
platelet
days
weeks in patients with high-titer hit antibodies
thrombocytopenia
heparin-dependent igg antibodies
specific platelet protein
platelet factor
pf
heparin-pf-igg
immune complex
platelets
causing platelet activation
activated platelets
release of platelet-derived procoagulant microparticles
coagulation reactions
thrombin
lmwhs
high cross-reactivity
circulating
circulating heparin-pf-igg immune complex
factors
higher risk
developing
developing hit-associated thrombosis
women
nonwhites
severity of thrombocytopenia
lower body weight
complications
hit
exacerbation of venous thromboembolism
venous thrombosis
limb gangrene
stroke
skin necrosis
antibodies
hit
months
use of unfractionated heparin
lmwh
patient with a history of hit if the antibody test
patients
undergoing spinal/epidural anesthesia
puncture
low molecular weight heparins
heparinoids
risk for long-term
permanent paralysis
spinal hematoma
risk of these events
use
indwelling
indwelling epidural catheters
concomitant use of platelet inhibitors
other anticoagulants
drugs
hemostasis
hematologic adverse effects
hemorrhage
postoperative blood loss
bruising
wound hematoma
incidence
bleeding complications
heparin
thrombocytopenia
heparin
low molecular weight heparins
danaparoid
useful substitute for heparin
low molecular weight heparins in thrombocytopenia for the majority of patients
immediate anticoagulation
thrombocytopenia
patients
local effects
injection site discomfort
bruising
incidence
bruising
heparin
hypersensitivity reactions
type
ige
hypersensitivity
cutaneous reaction
subcutaneous injection danaparoid
active ingredient
orgaran
reaction
side effects of orgaran
fda
healthcare professional for medical advice
bleeding gums
coughing up blood
difficulty in breathing
swallowing
dizziness
headache
increased menstrual flow
vaginal bleeding
nosebleeds
paralysis
prolonged bleeding from cuts
tarry stools
dark brown urine
shortness of breath
unexplained pain
swelling
discomfort
chest
abdomen
joints
muscles
unusual bruising 
vomiting of blood
coffee
groundlike material
weakness
back pain
burning
pricking
tickling
tingling sensation
leg weakness
numbness
problems with bowel
bladder function
fever
skin rash
pain at injection site
constipation
nausea